Data sharing

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment – GlobeNewswire

CONTEXT:  Good to see real world data alongside clinical trial data to reinforce the need to diagnose children with SMA early so that effective treatment can be given. IMPACT:  Medium Continue Reading

Posted On :